Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities (Tables)

v3.22.2
Accrued Expenses and Other Liabilities (Tables)
6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued Expenses, summarized by major category, as of June 30, 2022 and December 31, 2021 consist of the following: 

 

    June 30, 2022     December 31, 2021  
Payroll and incentives   $ 974     $ 1,343  
General and administrative expenses     404       195  
Research and development expenses     376       381  
Deferred revenue *     2,096       33  
Other deferred liabilities **     444       899  
Total   $ 4,294     $ 2,851  

 

*

At June 30, 2022, the balance included $2,063 thousand related to the BioNTech Agreement and $33 thousand is related to the Genentech Agreement. At December 31, 2021, the balance of $33 thousand of deferred revenue was related to the Genentech Agreement. The balance of the BioNTech Agreement will be recognized evenly over the next nine months. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).

 

 

** At June 30, 2022, the balance of $444 thousand is related to the CFF Agreement’s deferred liability. At December 31, 2021, the balance of $899 thousand was related to the CFF Agreement’s deferred liability. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).